Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans

被引:209
作者
Ghotbi, Roza
Christensen, Magnus
Roh, Hyung-Keun
Ingelman-Sundberg, Magnus
Aklillu, Eleni
Bertilsson, Leif
机构
[1] Huddinge Univ Hosp, Karolinska Inst, Div Clin Pharmacol, S-14186 Huddinge, Sweden
[2] Inha Univ Hosp, Div Clin Pharmacol, Dept Internal Med, Inchon 400711, South Korea
[3] Karolinska Inst, Dept Physiol & Pharmacol, Pharmacogenet Sect, S-17177 Stockholm, Sweden
关键词
caffeine; CYP1A2; haplotype; phenotype; polymorphism;
D O I
10.1007/s00228-007-0288-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives To investigate the CYP1A2 genotype-phenotype relationship and to compare CYP1A2 genetic polymorphisms and enzyme activity in terms of the effect of smoking and oral contraceptive (OC) use in Swedes and Koreans. Methods CYP1A2 enzyme activity was determined in 194 and 150 healthy Swedish and Korean subjects, respectively, on the basis of the 4-h plasma paraxanthine/caffeine (17X/137X) ratio determined using high-performance liquid chromatography. Genotyping for the -3860G > A, -2467delT, -739 T > G, -729 C > T, -163C > A and -3113A > G polymorphisms was performed by PCR-restriction fragment length polymorphism analysis. Results The mean 17X/137X ratio was 1.54-fold higher in Swedes than in Koreans (mean difference: 0.16; 95% CI of the mean difference: 0.12, 0.20; p < 0.0001). Smokers had a significantly higher 17X/137X ratio (higher CYP1A2 activity) than non-smokers, while Swedish OC users had a significantly lower 17X/137X ratio than non-users (mean difference: 0.31, 95% CI of the mean difference: 0.23, 0.39; p < 0.0001). No effect of gender differences on enzyme activity was observed. Four known (CYP1A2*1A, *1D, *1F, and *1L) and two novel haplotypes (CYP1A2*1V and CYP1A2*1W) were found. CYP1A2*1K was rare in Swedes and absent in Koreans. No significant genotype-phenotype relationship was observed, with the exception of CYP1A2*1F in Swedish smokers, where it was associated with higher enzyme inducibility (p=0.02). Koreans displayed a significantly lower mean 17X/137X ratio than Swedes having the same CYP1A2 genotype, smoking habit and OC use. Conclusions We found significant differences in CYP1A2 enzyme activity between Swedes and Koreans that could not be explained by environmental factors or the CYP1A2 haplotypes examined, despite differences in allele frequencies. None of the investigated CYP1A2 haplotypes are critical in inducing variations in enzyme activity, with the exception of CYP1A2*1F.
引用
收藏
页码:537 / 546
页数:10
相关论文
共 29 条
[1]   IMPAIRMENT OF CAFFEINE CLEARANCE BY CHRONIC USE OF LOW-DOSE ESTROGEN-CONTAINING ORAL-CONTRACEPTIVES [J].
ABERNETHY, DR ;
TODD, EL .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1985, 28 (04) :425-428
[2]   Genetic polymorphism of CYP1A2 in ethiopians affecting induction and expression: Characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1 [J].
Aklillu, E ;
Carrillo, JA ;
Makonnen, E ;
Hellman, K ;
Pitarque, M ;
Bertilsson, L ;
Ingelman-Sundberg, M .
MOLECULAR PHARMACOLOGY, 2003, 64 (03) :659-669
[3]   Identification of a novel splice-site mutation in the CYP1A2 gene [J].
Allorge, D ;
Chevalier, D ;
Lo-Guidice, JM ;
Cauffiez, C ;
Suard, F ;
Baumann, P ;
Eap, CB ;
Broly, F .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 56 (03) :341-344
[4]   CLOZAPINE DISPOSITION COVARIES WITH CYP1A2 ACTIVITY DETERMINED BY A CAFFEINE TEST [J].
BERTILSSON, L ;
CARRILLO, JA ;
DAHL, ML ;
LLERENA, A ;
ALM, C ;
BONDESSON, U ;
LINDSTROM, L ;
DELARUBIA, IR ;
RAMOS, S ;
BENITEZ, J .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 38 (05) :471-473
[5]   Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine [J].
Carrillo, JA ;
Christensen, M ;
Ramos, SI ;
Alm, C ;
Dahl, ML ;
Benítez, J ;
Bertilsson, L .
THERAPEUTIC DRUG MONITORING, 2000, 22 (04) :409-417
[6]   The G-113A polymorphism in CYP1A2 affects the caffeine metabolic ratio in a Chinese population [J].
Chen, XP ;
Wang, LQ ;
Zhi, LT ;
Zhou, GQ ;
Wang, HJ ;
Zhang, XM ;
Hao, BT ;
Zhu, YP ;
Cheng, Z ;
He, FC .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (03) :249-259
[7]  
Chevalier D, 2001, Hum Mutat, V17, P355, DOI 10.1002/humu.48
[8]   Detection of three genetic polymorphisms in the 5′-flanking region and intron 1 of human CYP1A2 in the Japanese population [J].
Chida, M ;
Yokoi, T ;
Fukui, T ;
Kinoshita, M ;
Yokota, J ;
Kamataki, T .
JAPANESE JOURNAL OF CANCER RESEARCH, 1999, 90 (09) :899-902
[9]   The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes [J].
Christensen, M ;
Andersson, K ;
Dalén, P ;
Mirghani, RA ;
Muirhead, GJ ;
Nordmark, A ;
Tybring, G ;
Wahlberg, A ;
Yasar, Ü ;
Bertilsson, L .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (06) :517-528
[10]  
CONNEY AH, 1976, CLIN PHARMACOL THER, V20, P633